Aparna Raj Parikh, MD, MS

home / authors / aparna-parikh-md-ms

Articles

Patient Profile: A 55-Year-Old With Colon Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Joleen M. Hubbard, MD;Aparna Raj Parikh, MD, MS

July 7th 2023

Experts on colorectal cancer present a patient case, offer their initial impressions, and discuss disease staging.

Unmet Needs and Future Perspectives on Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

June 5th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in colorectal cancer.

Trials Focused on ctDNA in Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.

Arvind Dasari, MD, MS, an expert on colorectal cancer

SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 29th 2023

An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.

Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.

T-DXd in Patients With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 22nd 2023

A comprehensive overview of trastuzumab deruxtecan (T-DXd) as a treatment for patients with HER2+ metastatic colorectal cancer.

Patient Profile: A 40-Year-Old Woman With Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.

Metastatic CRC: Role of ctDNA in Treatment Selection

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 15th 2023

Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.

PARADIGM Trial: Recent Data on EGFR-Targeting Therapy for mCRC

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Arvind Dasari, MD, MS, reviews the PARADIGM study on EGFR-targeting therapy in metastatic colorectal cancer.

Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 8th 2023

Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.

MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

Experts on HER2+ metastatic colorectal cancer review the MOUNTAINEER study on tucatinib plus trastuzumab.

Treatment Landscape for HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

May 1st 2023

An overview of the treatment landscape for HER2+ metastatic colorectal cancer and recent updates to the NCCN Guidelines.

Overview of HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.

Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS

April 24th 2023

A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.

Final Comments on ctDNA Testing in the Management of Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 17th 2023

The panel shares some closing thoughts on ctDNA testing in patients with colorectal cancer.

The Evolution of ctDNA Assays in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 17th 2023

The panel comments on how they see ctDNA assay usage evolving in colorectal cancer management.

Key Clinical Trial Data on ctDNA Assays in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 10th 2023

Stacey A. Cohen, MD, and Aparna Parikh, MD, MS, review the design and outcomes of key clinical trials exploring the use of ctDNA assays in colorectal cancer.

Utilizing ctDNA Assays in Colorectal Cancer for Treatment and Monitoring of Patients with Solid Tumors

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 10th 2023

The panel reviews the different settings in colorectal cancer where ctDNA is being investigated as a tool for treatment and monitoring.

Tumor-Naïve vs Tumor-Informed ctDNA Analyses in CRC Biomarker Testing

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 3rd 2023

Dr Daniel H. Ahn explains the logistical concerns of ctDNA testing in colorectal cancer.

Circulating Tumor DNA and its Use in Colorectal Cancer Treatment Decision-Making

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

March 3rd 2023

Aparna Parikh, MD, MS, defines circulating tumor DNA (ctDNA) and the use of ctDNA assays in colorectal cancer.

Emerging Biomarkers for Assessing Therapy Response in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 24th 2023

The panel discusses other emerging biomarkers for monitoring patient response to therapy for colorectal cancer.

Testing for Minimal Residual Disease (MRD) in Patients with Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 24th 2023

Dr Aparna Parikh explains minimal residual disease (MRD) in colorectal cancer and the logistical challenges of MRD testing.

Monitoring a Patient with Colorectal Cancer After Adjuvant Therapy

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 16th 2023

Dr Stacey A. Cohen discusses how she typically monitors patients with stage II and III colorectal cancer during and after adjuvant therapy.

Over- and Under-Treatment of Stage II and III Colorectal Cancer in the Adjuvant Setting

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 16th 2023

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, describe the challenges of deciding which patients with colorectal cancer should receive adjuvant therapy, and the risk of over- and under-treatment in later stages.

Considering a Patient with Colorectal Cancer for Adjuvant Chemotherapy

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 10th 2023

Aparna Parikh, MD, MS, details when she would recommend adjuvant chemotherapy to patients with similar presentations of colorectal cancer.

Patient Scenario: A 64-Year-Old Man with Stage II Colon Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

February 10th 2023

Tanios S. Bekaii-Saab, MD, presents a patient scenario of a 64-year-old man with stage 2 (pT3N0) colon cancer to the panel for discussion.

Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer

Ardaman Shergill, MD;Aparna Raj Parikh, MD, MS

October 17th 2022

Ardaman Shergill, MD, and Aparna Raj Parikh, MD, explore ongoing clinical investigations evaluating the use of circulating tumor DNA in the treatment of early-stage colon cancer.